Forte Biosciences (FBRX) Convertible Debt (2016 - 2017)
Forte Biosciences (FBRX) posted quarterly Convertible Debt of $11.0 million for Q1 2017, up 224.19% quarter-over-quarter from $3.4 million in Q4 2016.
Forte Biosciences (FBRX) Convertible Debt (2016 - 2017) Analysis & Trends
Forte Biosciences (FBRX) has reported Convertible Debt for 2 consecutive years, with $11.0 million the latest figure, recorded in Q1 2017.
- In Q1 2017, Convertible Debt changed N/A year-over-year to $11.0 million; the TTM figure through Mar 2017 stood at $11.0 million (changed N/A YoY), while the FY2016 annual figure was $3.4 million, changed N/A from the prior year.
- Convertible Debt rose to $11.0 million in Q1 2017 per FBRX's latest filing, from $3.4 million in the prior quarter.
- Across five years, Convertible Debt topped out at $11.0 million in Q1 2017 and bottomed at $3.4 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 11.02 Mn |
| Dec 31, 2016 | 3.40 Mn |